Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas

E. J. Dropcho, Steven Rosenfeld, R. B. Morawetz, J. Vitek, M. Brothers, T. Gorum, S. Bell, G. Y. Gillespie, M. Glantz, M. S. Mahaley, S. C. Schold

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) cisplatin. Patients and Methods: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast-enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. Results: Ten patients (45%) showed a greater than 25% decrease in the enhancing tumor area before radiotherapy with stabilization or improvement of neurologic deficits, and three patients (14%) had a greater than 70% decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. Conclusion: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.

Original languageEnglish (US)
Pages (from-to)452-458
Number of pages7
JournalJournal of Clinical Oncology
Volume10
Issue number3
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Glioma
Cisplatin
Neoplasms
Therapeutics
Radiotherapy
Optic Nerve Diseases
Brain Edema
Astrocytoma
Internal Carotid Artery
Glioblastoma
Neurologic Manifestations
Blood Vessels
Histology
Seizures
Biopsy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dropcho, E. J., Rosenfeld, S., Morawetz, R. B., Vitek, J., Brothers, M., Gorum, T., ... Schold, S. C. (1992). Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. Journal of Clinical Oncology, 10(3), 452-458. https://doi.org/10.1200/JCO.1992.10.3.452

Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. / Dropcho, E. J.; Rosenfeld, Steven; Morawetz, R. B.; Vitek, J.; Brothers, M.; Gorum, T.; Bell, S.; Gillespie, G. Y.; Glantz, M.; Mahaley, M. S.; Schold, S. C.

In: Journal of Clinical Oncology, Vol. 10, No. 3, 01.01.1992, p. 452-458.

Research output: Contribution to journalArticle

Dropcho, EJ, Rosenfeld, S, Morawetz, RB, Vitek, J, Brothers, M, Gorum, T, Bell, S, Gillespie, GY, Glantz, M, Mahaley, MS & Schold, SC 1992, 'Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas', Journal of Clinical Oncology, vol. 10, no. 3, pp. 452-458. https://doi.org/10.1200/JCO.1992.10.3.452
Dropcho, E. J. ; Rosenfeld, Steven ; Morawetz, R. B. ; Vitek, J. ; Brothers, M. ; Gorum, T. ; Bell, S. ; Gillespie, G. Y. ; Glantz, M. ; Mahaley, M. S. ; Schold, S. C. / Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 3. pp. 452-458.
@article{a6ed7551954e480eb94c7a07f4562766,
title = "Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas",
abstract = "Purpose: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) cisplatin. Patients and Methods: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast-enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. Results: Ten patients (45{\%}) showed a greater than 25{\%} decrease in the enhancing tumor area before radiotherapy with stabilization or improvement of neurologic deficits, and three patients (14{\%}) had a greater than 70{\%} decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. Conclusion: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.",
author = "Dropcho, {E. J.} and Steven Rosenfeld and Morawetz, {R. B.} and J. Vitek and M. Brothers and T. Gorum and S. Bell and Gillespie, {G. Y.} and M. Glantz and Mahaley, {M. S.} and Schold, {S. C.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1200/JCO.1992.10.3.452",
language = "English (US)",
volume = "10",
pages = "452--458",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas

AU - Dropcho, E. J.

AU - Rosenfeld, Steven

AU - Morawetz, R. B.

AU - Vitek, J.

AU - Brothers, M.

AU - Gorum, T.

AU - Bell, S.

AU - Gillespie, G. Y.

AU - Glantz, M.

AU - Mahaley, M. S.

AU - Schold, S. C.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Purpose: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) cisplatin. Patients and Methods: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast-enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. Results: Ten patients (45%) showed a greater than 25% decrease in the enhancing tumor area before radiotherapy with stabilization or improvement of neurologic deficits, and three patients (14%) had a greater than 70% decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. Conclusion: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.

AB - Purpose: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) cisplatin. Patients and Methods: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast-enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. Results: Ten patients (45%) showed a greater than 25% decrease in the enhancing tumor area before radiotherapy with stabilization or improvement of neurologic deficits, and three patients (14%) had a greater than 70% decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. Conclusion: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.

UR - http://www.scopus.com/inward/record.url?scp=0026510256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026510256&partnerID=8YFLogxK

U2 - 10.1200/JCO.1992.10.3.452

DO - 10.1200/JCO.1992.10.3.452

M3 - Article

C2 - 1311026

AN - SCOPUS:0026510256

VL - 10

SP - 452

EP - 458

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -